(Q30326960)

18 June 2017

1 reference

title

Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? (English)

1 reference

18 June 2017

J Esparza

1

1 reference

18 June 2017

N Bhamarapravati

series ordinal

2

1 reference

18 June 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

18 June 2017

1 reference

18 June 2017

volume

355

1 reference

18 June 2017

issue

9220

1 reference

18 June 2017

page(s)

2061-2066

1 reference

New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview

18 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

HIV-1 DNA vaccines and chemokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Some important issues in the planning of phase III HIV vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

The business of science and the science of business in the quest for an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Immune correlates of protection from HIV and AIDS – more answers but yet more questions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Viral envelope fails to deliver?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Towards an AIDS vaccine: the role of nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

The highest attainable standard: ethical issues in AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Ethical considerations in international HIV vaccine trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

The introduction of new vaccines into developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

Low-efficacy HIV vaccines: potential for community-based intervention programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902360-6

7 January 2021

10.1016/S0140-6736(00)02360-6

Identifiers

DOI

1 reference

release_53ehh7lqkjambnr2vo6uacehiq

18 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/53ehh7lqkjambnr2vo6uacehiq

24 November 2022

mapped directly with Wikidata item

1 reference